Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING

Age-Related Macular Degeneration Benchmark Imaging Dataset (ABID)

NCT06924021 · View on ClinicalTrials.gov ↗

Study Summary

1000 participants from up to 25 international locations who are at least 50 years old with either healthy eyes or a diagnosis of Age-Related Macular Degeneration (AMD) will be consented to provide images of their eyes for a new dataset. This dataset is an important step in developing an Artificial Intelligence (AI) based screening tool for AMD.

Interventions

  • OTHER Retinal Imaging

Study Locations (14)

Other

  • Charles Research Center — Buenos Aires
  • Adelaide Eye and Retina Centre — Adelaide
  • Centre Hospialier Intercommunal de Paradis (Centre Monticelli Paradis) — Marseille
  • University of Bonn - Department of Ophthalmology — Bonn
  • Aga Khan University — Karachi

Texas

  • Retina Foundation of the Southwest — Dallas
  • Valley Retina Institute — McAllen
  • Retina Consultants of Texas (Houston) — The Woodlands

Tamil Nadu

  • Sankara Nethralaya, Medical Research Foundation — Chennai
  • Aravind Eye Hospital — Chennai

North Dakota

  • Bergstrom Eye Research LLC — Fargo

Pennsylvania

  • Erie Retina Research — Erie

Utah

  • University of Utah - John A. Moran Eye Center — Salt Lake City

Wisconsin

  • University Station Eye Care Clinic — Madison

Trial Details

FieldValue
Enrollment Target 1,000 participants
Start Date 2025-05-12
Est. Completion 2026-11

Sponsor

University of Wisconsin, Madison

943 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06924021

The ClinicalTrials.gov registry entry for NCT06924021 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Wisconsin, Madison, which has 943 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Age-Related Macular Degeneration appearing as the primary indexed condition, and to 1 intervention — of which Retinal Imaging is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT06924021 reports 14 study locations spanning 7 distinct geographic areas — top geographies include Other, Texas, Tamil Nadu. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT06924021 about?

NCT06924021 is a clinical study titled "Age-Related Macular Degeneration Benchmark Imaging Dataset (ABID)". 1000 participants from up to 25 international locations who are at least 50 years old with either healthy eyes or a diagnosis of Age-Related Macular Degeneration (AMD) will be consented to provide images of their eyes for a new dataset. This dataset is an important step in developing an Artificial I...

What is the current status of trial NCT06924021?

This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2025-05-12. Estimated completion is 2026-11.

What conditions does trial NCT06924021 study?

This clinical trial studies the following conditions: Age-Related Macular Degeneration. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT06924021?

The interventions under investigation include: Retinal Imaging (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT06924021?

This trial is sponsored by University of Wisconsin, Madison, which has 943 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT06924021 being conducted?

This trial has 14 study locations across North Dakota, Pennsylvania, Texas, Utah, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial